Small Stocks, Big Money™

Enlivex Therapeutics (Nasdaq: ENLV) dosed the first patient in a Phase I trial evaluating Allocetra™ for TMJ osteoarthritis—a debilitating condition with no long-term effective treatment that affects up to 12% of the global population. The study, led by Sheba Medical Center, aims to showcase Allocetra’s potential as a first-of-its-kind immunotherapy for this high-need, multibillion-dollar market.

Connect Biopharma(Nasdaq: CNTB) published impressive Phase 2 results for rademikibart in the American Journal of Respiratory and Critical Care Medicine, highlighting a +420 mL FEV1 improvement in eosinophilic asthma patients—among the highest reported for any biologic. With rapid onset, sustained efficacy, and a clean safety profile, rademikibart is emerging as a potential best-in-class therapy for asthma and COPD, targeting a U.S. market of over 2 million patients facing acute exacerbations annually.

Venu Holding Corporation (NYSE American: VENU) continues its rapid sales growth, reporting a record-breaking $17.1 million in Luxe FireSuite sales for March—up 52% month-over-month—powered by a game-changing structured financing model. With $77.7 million in sales for fiscal 2024 (a 250% YoY jump) and rapid expansion into key entertainment markets, VENU is on track to hit its $200 million goal as it redefines premium live entertainment ownership.

Greenwich LifeSciences (Nasdaq: GLSI) announced positive preliminary immune response data from its Phase III FLAMINGO-01 trial, showing strong immune activation across both HLA-A02 and non-HLA-A02 breast cancer patients. These results not only validate prior Phase IIb findings, but also position GLSI-100 to potentially double its eligible market to 88,000 patients annually—unlocking an estimated $8–10 billion market opportunity in the U.S. and Europe.